Authors
Vilmarie Rodriguez, Meenakshi Devidas, Zhiguo Bruce Chen, Andrew J Carroll, Nyla A Heerema, Michael J Borowitz, Brent L Wood, William L Carroll, Naomi J Winick, Elizabeth A Raetz, Mignon L Loh, Michael J Burke, Wanda L Salzer, Stephen P Hunger, Karen R Rabin
Publication date
2023/11/28
Journal
Blood
Volume
142
Pages
824
Publisher
Content Repository Only!
Description
Introduction: Children with Down syndrome (DS) have a 20-fold increased risk of developing B-acute lymphoblastic leukemia (B-ALL), and demonstrate an increased risk of both relapse and treatment-related mortality (TRM). The Children's Oncology Group (COG) High-Risk (HR) B-ALL trial AALL0232 was permanently closed to DS HR patients due to excessive TRM, primarily due to overwhelming sepsis during times of severe neutropenia. On the successor HR B-ALL trial AALL1131, a primary objective for DS patients was therefore to reduce TRM by enhancing supportive care and modifying some elements of therapy.
Methods: DS HR patients were treated on a single non-randomized stratum, with several modifications compared to non-DS HR patients. The majority of DS HR patients received a three-drug Induction, with only slow early responders (M2/M3 marrow at Induction day 15) receiving a single dose of …
Total citations
20241
Scholar articles
V Rodriguez, M Devidas, ZB Chen, AJ Carroll… - Blood, 2023